Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 4/20 | 0.33 |
| ▸ | CA9 | Q16790 | 4/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6499014 | 0.76 | CA12 (0.38) | PREPCA12CA1CA9HSP90AA1 | |
| SCHEMBL6434920 | 0.76 | CA12 (0.37) | PREPCA12CA1CA9HSP90AA1 | |
| SCHEMBL6433055 | 0.75 | CA12 (0.37) | PREPCA12CA1CA9HSP90AA1 | |
| SCHEMBL6433061 | 0.75 | CA12 (0.37) | PREPCA12CA1CA9HSP90AA1 | |
| SCHEMBL7701156 | 0.73 | DRD2 (0.33) | PREPCA12CA1CA9HSP90AA1 | |
| SCHEMBL6434340 | 0.73 | CA12 (0.39) | PREPCA12CA1CA9HSP90AA1 | |
| SCHEMBL5619277 | 0.73 | TYR (0.38) | HSP90AA1 | |
| SCHEMBL6435288 | 0.73 | MTNR1A (0.37) | PREPCA12CA1CA9HSP90AA1 | |
| SCHEMBL6433452 | 0.73 | MTNR1A (0.37) | PREPCA12CA1CA9HSP90AA1 | |
| SCHEMBL6433944 | 0.72 | CA12 (0.39) | PREPCA12CA1CA9HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6797731-B2 | USE AS SKIN LIGHTENING AGENTS | PFIZER INC. | 2004-09-28 | — | — | US | disclosed |
| US-20030190298-A1 | Resorcinol derivatives | BRADLEY STUART E (GB) | 2003-10-09 | — | — | US | disclosed |
| US-20020137961-A1 | Resorcinol derivatives | PFIZER INC. | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030190298-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | PREP 1379/4885CA12 4635/4885CA1 4874/4885 |
| US-20020137961-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | PREP 1379/4885CA12 4635/4885CA1 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.